ArticleBMC cancer2025
Prognostic value of integrated inflammatory-nutritional evaluation in neoadjuvant-treated rectal cancer: a retrospective cohort analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gustave Roussy Immune (GRIm) score as a novel prognostic biomarker for gastrointestinal cancers: a meta-analysis of sixteen studies.World journal of surgical oncology · 2026Pooled it
- Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory responses, immune status, and nutritional conditions are critical determinants of tumor progression and treatment outcomes in rectal cancer. However, the prognostic value of integrated inflammatory-nutritional scores, including the modified Gustave Roussy Immune (mGRIm) score and modified Naples Prognostic Score (M-NPS), remains underexplored in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (nCRT). This study aimed to evaluate the prognostic significance of these scores and to develop a nomogram for identifying patient groups who may benefit from nCRT.
methodsA retrospective cohort study analyzed 157 rectal cancer patients who received nCRT, followed by total mesorectal excision (TME) and adjuvant chemotherapy at a single institution. The mGRIm score (based on lactate dehydrogenase [LDH], serum albumin, and neutrophil-to-lymphocyte ratio [NLR]) and M-NPS (incorporating albumin, total cholesterol, NLR, and lymphocyte-to-monocyte ratio [LMR]) were calculated. Patients were stratified into high- and low-score groups based on these prognostic scores. Kaplan–Meier analysis and Cox regression were used to assess associations with overall survival (OS) and progression-free survival (PFS). A nomogram integrating independent prognostic factors was developed and validated.
resultsHigh mGRIm and M-NPS scores were significantly associated with worse OS (p < 0.05, p < 0.01) and PFS (both p < 0.05). Multivariate Cox analysis identified tumor length > 5 cm, pre-radiotherapy metastasis, and high M-NPS as independent predictors of OS, while high mGRIm, advanced N stage, and metastasis predicted inferior PFS. The nomogram demonstrated robust predictive accuracy for 1-, 2-, and 3-year OS (AUC: 0.790, 0.739, 0.708) and PFS (AUC: 0.763, 0.727, 0.786), with excellent calibration.
conclusionThe mGRIm score and M-NPS are independent prognostic indicators for rectal cancer patients receiving nCRT. The novel nomogram, integrating these biomarker scores with clinical staging parameters, enables the quantification of individual prognosis before treatment initiation and facilitates the identification of optimal nCRT candidates through multivariable probability estimation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.